Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Yolanda Barbáchano(Royal Marsden NHS Foundation Trust), Stephen Falk(At Bristol), Jonathan Wadsley(Weston Park Cancer Centre), Justin S. Waters(Maidstone Hospital), Ian Chau(Royal Marsden NHS Foundation Trust), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), Clare Peckitt(Royal Marsden NHS Foundation Trust), Tom Crosby(Southampton General Hospital), Alicia Okines(Royal Marsden NHS Foundation Trust), Wasat Mansoor(The Christie NHS Foundation Trust), Claire Saffery(Royal Marsden NHS Foundation Trust), David A. Smith(Compass Oncology), David González de Castro(Complejo Hospitalario de Salamanca), David Ferry(Eli Lilly (United States)), Sarah Slater(Barts Health NHS Trust), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Andrew Wotherspoon(Université Libre de Bruxelles)
Cited by 728
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k